Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing studyJianmeng Chen, Charles Flexner, Rosa G Liberman, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 2019
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamideMaddalena Cerrone, Omamah Alfarisi, Megan Neary, et al.
Nature Communications|March 31, 2019
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapiesJames J Hobson, Amer Al-Khouja, Paul Curley, et al.
AIDS Research and Human Retroviruses|January 11, 2008
Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patientsRahul P Bakshi, Fayez Hamzeh, Ian Frank, et al.
Nanoscale Advances|September 22, 2022
Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulationsJames J Hobson, Paul Curley, Alison C Savage, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 1, 2006
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoringRichard E Nettles, Tara L Kieffer, Teresa Parsons, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 4, 2008
Slow efavirenz metabolism genotype is common in BotswanaRobert Gross, Richard Aplenc, Thomas Tenhave, et al.
Clinical Pharmacology and Therapeutics|October 28, 2020
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic DevelopmentMarta Boffito, David J Back, Charles Flexner, et al.
Annals of Internal Medicine|February 28, 2022
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug InteractionsCatia Marzolini, Daniel R Kuritzkes, Fiona Marra, et al.
The Lancet. Global Health|March 26, 2021
The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing studyJianmeng Chen, Charles Flexner, Rosa G Liberman, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 2019
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamideMaddalena Cerrone, Omamah Alfarisi, Megan Neary, et al.
Nature Communications|March 31, 2019
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapiesJames J Hobson, Amer Al-Khouja, Paul Curley, et al.
AIDS Research and Human Retroviruses|January 11, 2008
Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patientsRahul P Bakshi, Fayez Hamzeh, Ian Frank, et al.
Nanoscale Advances|September 22, 2022
Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulationsJames J Hobson, Paul Curley, Alison C Savage, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 1, 2006
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoringRichard E Nettles, Tara L Kieffer, Teresa Parsons, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 4, 2008
Slow efavirenz metabolism genotype is common in BotswanaRobert Gross, Richard Aplenc, Thomas Tenhave, et al.
Clinical Pharmacology and Therapeutics|October 28, 2020
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic DevelopmentMarta Boffito, David J Back, Charles Flexner, et al.
Annals of Internal Medicine|February 28, 2022
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug InteractionsCatia Marzolini, Daniel R Kuritzkes, Fiona Marra, et al.
The Lancet. Global Health|March 26, 2021
The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
Pageof 14